iBio Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
Sep. 30, 2025
Commitments and Contingencies
Commitments and Contingencies	19. Commitments and Contingencies CRO Agreements In fiscal year 2025, the Company entered into agreements with three CROs for CMC development, non-clinical toxicology and related studies to advance IBIO-600 and IBIO-610 towards clinical testing. The Company incurred costs of approximately $2.3 million for the three months ended September 30, 2025 and has incurred total costs of approximately $4.5 million since the projects’ inception. The Company is committed to additional costs totaling approximately $5.5 million as of the date of this Quarterly Report.

Commitments and Contingencies

3 Months Ended

Sep. 30, 2025

Commitments and Contingencies

Commitments and Contingencies

19. Commitments and Contingencies

CRO Agreements

In fiscal year 2025, the Company entered into agreements with three CROs for CMC development, non-clinical toxicology and related studies to advance IBIO-600 and IBIO-610 towards clinical testing. The Company incurred costs of approximately $2.3 million for the three months ended September 30, 2025 and has incurred total costs of approximately $4.5 million since the projects’ inception. The Company is committed to additional costs totaling approximately $5.5 million as of the date of this Quarterly Report.